MX2022008036A - Nuevo uso de formulacion inmunogenica bcg que expresa una proteina de virus respiratorio sincicial contra hmpv. - Google Patents

Nuevo uso de formulacion inmunogenica bcg que expresa una proteina de virus respiratorio sincicial contra hmpv.

Info

Publication number
MX2022008036A
MX2022008036A MX2022008036A MX2022008036A MX2022008036A MX 2022008036 A MX2022008036 A MX 2022008036A MX 2022008036 A MX2022008036 A MX 2022008036A MX 2022008036 A MX2022008036 A MX 2022008036A MX 2022008036 A MX2022008036 A MX 2022008036A
Authority
MX
Mexico
Prior art keywords
expresses
immunogenic formulation
new use
virus protein
protein against
Prior art date
Application number
MX2022008036A
Other languages
English (en)
Inventor
Alexis Kalergis
Susan Bueno
Pablo González
Original Assignee
Univ Pontificia Catolica Chile
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pontificia Catolica Chile filed Critical Univ Pontificia Catolica Chile
Publication of MX2022008036A publication Critical patent/MX2022008036A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La invención se refiere al nuevo uso de una formulación inmunogénica que contiene la cepa Bacilo de Calmette y Guerin (BCG) en una concentración entre 104-109 bacterias, que expresa al menos una proteína o fragmento inmunogénico del virus respiratorio sincicial (VRS, Human orthopneumovirus), en una solución tampón salina farmacéuticamente aceptable porque sirve para preparar una vacuna útil para prevenir prevenir, tratar, o atenuar infecciones de metapneumovirus humano (hMPV).
MX2022008036A 2019-12-26 2020-12-24 Nuevo uso de formulacion inmunogenica bcg que expresa una proteina de virus respiratorio sincicial contra hmpv. MX2022008036A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CL2019003847A CL2019003847A1 (es) 2019-12-26 2019-12-26 Nuevo uso de formulación inmunogénica bcg que expresa una proteína de virus respiratorio sincicial contra hmpv
PCT/CL2020/050193 WO2021127797A1 (es) 2019-12-26 2020-12-24 NUEVO USO DE FORMULACIÓN INMUNOGÉNICA BCG QUE EXPRESA UNA PROTEÍNA DE VIRUS RESPIRATORIO SINCICIAL CONTRA hMPV

Publications (1)

Publication Number Publication Date
MX2022008036A true MX2022008036A (es) 2022-08-22

Family

ID=76573373

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022008036A MX2022008036A (es) 2019-12-26 2020-12-24 Nuevo uso de formulacion inmunogenica bcg que expresa una proteina de virus respiratorio sincicial contra hmpv.

Country Status (9)

Country Link
US (1) US12667611B2 (es)
EP (1) EP4082566A4 (es)
JP (1) JP7706773B2 (es)
CN (1) CN115023238A (es)
AR (1) AR120887A1 (es)
CL (1) CL2019003847A1 (es)
MX (1) MX2022008036A (es)
PE (1) PE20221731A1 (es)
WO (1) WO2021127797A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2020002568A1 (es) * 2020-10-05 2022-08-05 Univ Pontificia Catolica Chile Formulación inmunogénica que contiene una cepa bcg modificada que expresa una proteína de andesvirus (andv) útil para prevenir y tratar infecciones por virus hanta-andv

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG149013A1 (en) * 2003-12-17 2009-01-29 Wyeth Corp Immunogenic peptide carrier conjugates and methods of producing same
CL2007002710A1 (es) * 2007-09-20 2008-01-04 Univ Pontificia Catolica Chile Formulacion inmunogenica que confiere proteccion contra la infeccion o patologia causada por el virus respiratorio sincicial (vrs) que comprende una cepa recombinante atenuada de mycobacterium; y uso de la formulacion inmunogenica para preparar una vacuna para prevenir, tratar o atenuar infecciones del vrs.
CL2013002829A1 (es) * 2013-10-01 2014-04-04 Univ Pontificia Catolica Chile Formulacion inmunogenica que contiene bcg vivas recombinantes que expresan antigenos de metapneumovirus (hmpv) en una suspension que se prepara a partir de un liofilizado sin la necesidad de adjuvante; su uso farmaceutico; vacuna contra hmpv.
CN108348593B (zh) * 2015-08-31 2022-08-16 泰克诺瓦克斯股份有限公司 基于人呼吸道合胞病毒(hrsv)病毒样颗粒(vlps)的疫苗
WO2018005769A1 (en) * 2016-06-29 2018-01-04 Duke University Compositions and methods for activating antigen presenting cells with chimeric poliovirus

Also Published As

Publication number Publication date
PE20221731A1 (es) 2022-11-07
JP7706773B2 (ja) 2025-07-14
US12667611B2 (en) 2026-06-30
JP2023508505A (ja) 2023-03-02
EP4082566A4 (en) 2024-03-13
AR120887A1 (es) 2022-03-30
US20230055706A1 (en) 2023-02-23
CN115023238A (zh) 2022-09-06
WO2021127797A1 (es) 2021-07-01
EP4082566A1 (en) 2022-11-02
CL2019003847A1 (es) 2021-08-06

Similar Documents

Publication Publication Date Title
CO2021006308A2 (es) Proteínas f de prefusión del vrs estabilizadas
MX2023009527A (es) Degradadores de la cinasa 4 asociada al receptor de interleucina 1 (irak4) y usos de los mismos.
PH12021552736A1 (en) A subunit vaccine for treatment or prevention of a respiratory tract infection
PE20170673A1 (es) Terapia de combinacion para tratar una paramixovirus
MX2022015257A (es) Proteinas f de prefusion del virus respiratorio sincicial (vrs) solubles y estabilizadas.
PH12021550479A1 (en) Dengue vaccine unit dose and administration thereof
WO2021234160A3 (en) Ace2-fc fusion proteins and uses thereof
BR112016028816A2 (pt) combinação imunogênica, método para obter uma resposta imunológica específica, uso de uma combinação imunogênica, regime de vacinação para prevenção, redução ou tratamento de infecção por vírus sincicial respiratório, e, kit.
MX395525B (es) Composiciones inmunogenicas para usar en vacunas neumococicas.
PH12018502332A1 (en) Stabilized pre-fusion rsv f proteins
UA114286C2 (uk) Спосіб лікування staphylococcus aureus
MX2025006782A (es) Degradadores de la cinasa 4 asociada al receptor de interleucina-1 (irak4) y usos de los mismos
BR112017026061A2 (pt) composto, uso de um composto, e, método de tratamento de uma infecção viral
MX2020008454A (es) Composicion inmunogenica que comprende antigenos estafilococicos.
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
MX364800B (es) Tilmicosina de accion prolongada mejorada y el uso de la misma en el tratamiento del complejo respiratorio bovino (crb) y en el periodo de la vaca seca.
WO2019087083A3 (en) Oral delivery of glp-1 peptide analogs
MX2023004933A (es) Proteinas de fusion de ace2 y usos de las mismas.
CL2007002710A1 (es) Formulacion inmunogenica que confiere proteccion contra la infeccion o patologia causada por el virus respiratorio sincicial (vrs) que comprende una cepa recombinante atenuada de mycobacterium; y uso de la formulacion inmunogenica para preparar una vacuna para prevenir, tratar o atenuar infecciones del vrs.
MX2019002248A (es) Proteina de union al factor h modificada.
WO2023006935A3 (en) Ace2 fusion proteins and uses thereof
CL2019003847A1 (es) Nuevo uso de formulación inmunogénica bcg que expresa una proteína de virus respiratorio sincicial contra hmpv
BR112019001130A2 (pt) uso de lactama e composição farmacêutica
BR112022019207A2 (pt) Composições de vacina para coronavírus e métodos de uso das mesmas
MX2022001937A (es) Composicion inmunogenica.